Thanks Tommy.
Elmiron is available as capsules, and in sc injectable format, although it's not commonly prescribed, and is only approved for the treatment of IC.
My point was that, in my view, $1k - $2k per treatment course, is not a sensible starting point for a revenue projection, if PAR is looking to get this drug available on the PBS.
- Forums
- ASX - By Stock
- PAR
- The Future
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.44%
!
42.0¢

The Future, page-57
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $166.9M |
Open | High | Low | Value | Volume |
40.0¢ | 42.0¢ | 40.0¢ | $168.2K | 411.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 41.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 50665 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 0.410 |
3 | 15064 | 0.405 |
6 | 68425 | 0.400 |
4 | 67519 | 0.395 |
5 | 56650 | 0.390 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 50665 | 2 |
0.425 | 2860 | 1 |
0.430 | 28500 | 1 |
0.440 | 50372 | 3 |
0.445 | 1400 | 1 |
Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |